Picture loading failed.

Pre-Made Basiliximab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-049-1mg 1mg 3090
GMP-Bios-ab-049-10mg 10mg Inquiry
GMP-Bios-ab-049-100mg 100mg Inquiry
GMP-Bios-ab-049-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Basiliximab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody
INN Name Basiliximab
TargetIL2RA
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI Structure1mim:HL/3iu3:AB:CD:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed1996
Year Recommended1997
CompaniesCerimon Pharmaceuticals;Novartis
Conditions ApprovedRenal transplant rejection;Transplant rejection
Conditions Activena
Conditions DiscontinuedUlcerative colitis;Uveitis
Development Techna